dr. rini discusses asco 2023 data in frontline rcc: clear and keynote-426 trials
Published 1 year ago • 112 plays • Length 4:56Download video MP4
Download video MP3
Similar videos
-
11:23
panelists share how clear and keynote-426 data presented at asco 2023 impact treatment decisions
-
6:58
keynote-426 study
-
10:04
drs. rini, plimack discuss the latest frontline io/tki data in rcc from 2023 asco® annual meeting
-
13:35
asco gu 2020: dr. rini highlights key research efforts in kidney cancer
-
5:16
drs. brian rini and monty pal debate frontline rcc treatment options
-
3:33
renal cancer update from asco 2023
-
1:04:54
diabetes and the retina 2024
-
54:43
all-cause and immune checkpoint inhibitor-associated acute kidney injury
-
7:25
understanding cidp (chronic inflammatory demyelinating polyradiculoneuropathy)
-
5:46
brian rini, md, and monty pal, md, discuss rcc clinical trials
-
1:15
dr. plimack on updated findings of the keynote-426 study in rcc
-
9:28
rcc doublet considerations: immune-mediated toxicity, duration of treatment, and more
-
1:45
keynote-426: pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma
-
42:06
the uromigos: frontline therapy in rcc
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
58:43
the gu power hour updates (asco-2023)
-
9:52
phase 3 axitinib data in patients with previously treated advanced renal cell carcinoma
-
4:20
trial updates in mrcc from asco: keynote-427, resort, e2810 & immotion151
-
1:57
dr. agarwal discusses results of keynote-426 in mrcc
-
7:57
patient selection for io/io versus io/tki in the frontline setting
-
2:23
overview of a phase iii trial of pembrolizumab plus axitinib in rcc
-
1:33
dr. powles on the results of the keynote-426 trial in mrcc